The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Blair, P. J.
Right arrow Articles by June, C. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blair, P. J.
Right arrow Articles by June, C. H.
The Journal of Immunology, 1998, 160: 12-15.
Copyright © 1998 by The American Association of Immunologists

CUTTING EDGE

Cutting Edge: CTLA-4 Ligation Delivers a Unique Signal to Resting Human CD4 T Cells That Inhibits Interleukin-2 Secretion but Allows Bcl-XL Induction1

Patrick J. Blair*, James L. Riley{dagger}, Bruce L. Levine{ddagger}, Kelvin P. Lee*, Nancy Craighead*, Tara Francomano{ddagger}, Steven J. Perfetto{ddagger}, Gary S. Gray§, Beatriz M. Carreno§ and Carl H. June2,{ddagger}

* Naval Medical Research Institute, Bethesda, MD 20889; {dagger} Walter Reed Army Institute for Research, Rockville, MD 20850; {ddagger} Henry M. Jackson Foundation for the Advancement of Military Medicine, U.S. Military HIV Research Program, Bethesda, MD 20889; and § Genetics Institute, Inc., Cambridge, MA 02140


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results and Discussion
 References
 
We have assessed the functional effects of a panel of CTLA-4 mAbs on resting human CD4+ T cells. Our results demonstrate that some CTLA-4 mAbs can inhibit proliferative responses of resting CD4+ cells and cell cycle transition from G0 to G1. The inhibitory effects of CTLA-4 were evident within 4 h, at a time when cell surface CTLA-4 expression remained undetectable. Other CTLA-4 mAbs had no detectable inhibitory effects, indicating that binding of Ab to CTLA-4 alone is not sufficient to mediate down-regulation of T cell responses. Interestingly, while IL-2 production was shut off, inhibitory anti-CTLA-4 mAbs permitted induction and expression of the cell survival gene bcl-XL. Consistent with this observation, cells remained viable and apoptosis was not detected after CTLA-4 ligation.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results and Discussion
 References
 
CTLA-4 is a counter-regulatory relative of CD28 that delivers an opposing signal (1, 2). CTLA-4 and CD28 bind to both B7 ligands with low affinity but with rapid on and off rates (3). CTLA-4 mRNA expression is confined to the CD28+ subset of T cells, and mRNA is detected within 1 h after T cell activation (4, 5). Cell surface expression of CTLA-4 is not detectable on resting T cells and peaks 2 to 3 days after activation (6, 7). Previously, it has been shown that anti-CTLA-4 mAb plus anti-TCR mAb and suboptimal anti-CD28 mAb augmented proliferation in CD4+ T cell blasts (6). However, other evidence suggests that CTLA-4 activation opposes CD28-mediated costimulation and, in fact, may have a dominant negative regulatory role (7).

We have analyzed the functional effects of a panel of CTLA-4 mAbs coimmobilized with anti-CD3 and anti-CD28 mAb on resting primary human CD4+ T cells. Our results demonstrate that while some CTLA-4 mAbs blocked T cell activation, others had no effect. This CTLA-4-mediated inhibition induces a novel phenotype during the first 4 h of activation whereby IL-2 induction is prevented while enhancement of the cell survival gene bcl-XL is preserved.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results and Discussion
 References
 
Antibodies and cells

Antibodies used to stimulate cells included: the anti-CTLA-4 mAbs ER5.3D8 and ER5.3D6 (8); humanized anti-CD3 OKT3 (kindly provided by Dr. Jeffrey Bluestone); and anti-CD28 9.3 (9); anti-monomorphic HLA class I mAb W6/32 and anti-glycophorin A 10FTMC served as controls. Freshly isolated PBL were isolated from healthy donors, and CD4+ T cells were purified by negative selection (10). Mean cell volume (fl) was determined using a Coulter Counter Channelyzer (Coulter, Miami, FL).

Bead preparation

Anti-CD3, anti-CD28, and anti-CTLA-4 mAb were covalently attached to polyurethan-coated tosyl-activated Dynabeads (Dynal, Lake Success, NY) per manufacturer’s instructions (11) (bead-cell ratio, 1:1). Beads were prepared with a constant amount of anti-CD3 Ab that represented 5% of the total protein bound and a titration of anti-CD28 and anti-CTLA-4 or control mAb to make up the remaining 95%. Ab-coated beads were tested at anti-CD28-CTLA-4 ratios of 10:0, 9:1, 5:5, 3:7, 1:9, and 0:10. Ab loading was verified by staining beads with pretitered amounts of Abs against their specific isotype.

Proliferation and cytokine ELISA assays

Purified CD4+ T cells were cultured in 96-well plates at a density of 2 x 105 cells. Cultures were pulsed with 1 µCi of [3H]TdR for 18 h before harvest. IL-2 was assayed in supernatants by ELISA (Endogen, Inc., Cambridge, MA).

Cell cycle and apoptosis analysis

Bivariate analysis of cellular RNA and DNA content was performed by staining cells with the RNA-specific fluorochrome pyronin Y and the DNA-specific fluorochrome Hoechst 33342. Regions were determined using unstimulated T cells (12). Apoptosis was analyzed using a modified TUNEL-based (Tdt-mediated dUTP-biotin Nick end labeling) procedure (13).

Immunoprecipitation and Western blotting

Antibodies for immunoprecipitating Bcl-X (rabbit anti-Bcl-X polyclonal serum (14)) and Western blotting (ascites from the anti-human Bcl-X mAb, 2A1) were a kind gift from Dr. Craig Thompson. Cells were harvested after 72 h of stimulation and 1 x 107 cells lysed, immunoprecipitated, and Western blotted (13).

PCR-based liquid hybridization assay

We developed quantitative assays to measure steady state mRNA levels of IL-2 and bcl-XL. cDNAs were prepared from total RNA. Twofold dilutions of the RT product were amplified with the following primers to ensure that the PCR reactions were performed in a linear range:

bcl-XL: (S)-5'-GCTCCACATCACCCCAGGGACAGCA-3'

(AS)-3'-GTAGAGTGGATGGTCAGTGTCTGGT-3'

IL-2: (S)-5'-CAACTCCTGTCTTGCATTGC-3'

(AS)-5'-TTCTGTGGCCTTCTTGGG-3'

Liquid hybridization of the PCR products was then performed (15). Briefly, 200,000 counts of the following labeled oligonucleotides were added to 30 µl of each PCR reaction:

Bcl-xL: 5'-TACTTTTGTGGAACTCTATGGGAAC-3'

IL-2: 5'-ACAAGAATCCCAAACTCACCAGG-3'

Following hybridization, samples were separated on a 6% acrylamide gel and then exposed to a phosphorimager screen for 2 h.


   Results and Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results and Discussion
References
 
With a single exception (16), previous work with mouse T cells has shown that CTLA-4 opposes the costimulatory effects of CD28 (1, 17, 18, 19, 20, 21). In contrast, reports on human CTLA-4 function are more limited, and most indicate that CTLA-4 enhances costimulation (6, 22, 23). One study indicates that anti-human CTLA-4 mAbs can induce Ag-specific clonal deletion (8). To address this paradox, a panel of five anti-CTLA-4 mAbs was tested on human CD4 cells, with 3D6 and 3D8 chosen for detailed analysis.

We measured proliferation of human CD4+ T cells following stimulation using beads coated with constant amounts of anti-CD3 and varying amounts of anti-CD28/CTLA-4 mAbs (Fig. 1Go). Stimulation of CD4+ cells with the control anti-CD3/28/MHC I or anti-CD3/28/glycophorin A beads led to robust responses similar to those of anti-CD3/28 alone. Very little proliferation was evident when cultures were stimulated with coimmobilized anti-CD3 and anti-CTLA-4 mAbs alone. Increasing the ratio of anti-CTLA-4-anti-CD28 mAb led to markedly decreased proliferation in some of the cultures, most notably with the anti-CTLA-4 mAb 3D6. Inhibition was maintained in cultures cultured for up to 7 days (data not shown). Additionally, expression of CD25 IL-2R and CD69 were greatly diminished (data not shown). Inhibition was dependent on the ratio of anti-CD28 mAb to 3D6, implying that increasing levels of CD28 activation can circumvent inhibitory effects generated by CTLA-4 ligation. In contrast, beads containing the anti-CD3/CD28/CTLA-4 Ab 3D8 were not inhibitory. For all subsequent experiments, beads coated with anti-CD28/CTLA-4 at a ratio of 1:9 were used to explore the mechanism of inhibition by CTLA-4.



View larger version (26K):
[in this window]
[in a new window]
  		FIGURE 1. Distinct effects of CTLA-4 on T cell proliferation. Resting human CD4+ T cells (2 x 105) were stimulated with anti-CD3/28/CTLA-4 or anti-CD3/28/MHC I-coated Ab beads at 1 bead/cell. The ratio of CD28 to CTLA-4 or CD28 to MHC is shown at the left. Cells cultured at a 0:10 ratio are denoted by hatched bars, at 1:9 by filled bars, and at 3:7 by unfilled bars. Cultures were pulsed following 54 h of culture and then harvested after an additional 18 h. Right, IL-2 concentration (pg/ml) measured in culture supernatants after 24 h by ELISA. Data represent the mean ± SEM from three separate experiments using cells from different donors.

 
Previous studies in the mouse showed that anti-CTLA-4 prevented IL-2 secretion and did not affect T cell viability (19). To examine the mechanism of CTLA-4-mediated inhibition of T cell activation in the absence of cell death, we assessed whether CTLA-4 might affect cytokine secretion and bcl-XL expression. IL-2 and bcl-XL are regulated in part by CD28 (24, 25). Perturbation of these genes could account for the observed phenotype induced by CTLA-4 ligation. Therefore, we measured IL-2 in supernatants from cultures of CD4+ T cells stimulated with Ab-coated beads (Fig. 1Go). Cultures stimulated with anti-CD3/28 and the control anti-MHC I or 3D8 Ab secreted moderate amounts of IL-2. In contrast, cross-linking CD4+ T cells with 3D6 strongly inhibited IL-2 production.

We assayed IL-2 mRNA levels using a semiquantitative RT-PCR-based assay. A profound inhibition of IL-2 mRNA expression was induced by ligation with the anti-CTLA-4 mAb 3D6 within 4 h of culture (Fig. 2GoA). Samples that were stimulated with anti-CD3/28 and 3D6 had roughly 35-fold less IL-2 mRNA than samples stimulated with the noninhibitory anti-CTLA-4 3D8 or MHC I mAb. Our results extend the inhibitory effects of CTLA-4 to a much earlier phase of T cell activation than was previously identified (19). These results are important since we and others (6) have been unable to demonstrate surface CTLA-4 expression on resting T cells, although we have found induction of CTLA-4 mRNA in T cells within 1 h after stimulation by anti-CD3/28 (4). Thus, despite low levels of surface expression, CTLA-4 ligation results in potent inhibition. The ability of CTLA-4 to inhibit early IL-2 induction is consistent with the proposed role of CTLA-4 for induction of CD4 T cell anergy (26). As has been previously reported for mouse T cells (19), inhibition of proliferation by inhibitory anti-CTLA-4 Ab can be partially reversed by addition of exogenous IL-2 (data not shown).



View larger version (53K):
[in this window]
[in a new window]
  		FIGURE 2. Distinct effects of CTLA-4 ligation on IL-2 and bcl-XL expression during early T cell activation. (A) CD4+ cells were cultured with Ab-coated beads containing constant amounts of anti-CD3 mAb and anti-CD28/CTLA-4 or CD28/MHC I at a 1:9 ratio. IL-2, and Bcl-XL mRNA expression was measured at 4 h. Semiquantitative RT-PCR utilizing liquid hybridization was performed as described in Materials and Methods. Samples that lacked reverse transcriptase (NO) were included for each condition to exclude contamination with genomic DNA and dilutions of RT products in microliters (2.5, 5, 10) are shown above the lanes. Samples were equilibrated on rRNA levels. B, Results at 48 h following stimulation with anti-CD3 and anti-MHC I or CTLA-4 mAbs alone. C, Induction of Bcl-XL in response to costimulation by anti-CD3/28/glycophorin A, CD3/28/CTLA4 3D8, and CD3/28/CTLA4 3D6. The anti-CD28-CTLA-4 ratio of the beads in this experiment was 1:9. CD4 T cells were stimulated for 72 h as indicated, and extracts from 1 x 107 cells per sample were subjected to sequential immunoprecipitation and immunoblotting. The position of Bcl-XL (29 kDa) is indicated. The percent of apoptosis in cultured CD4+ T cells as determined by TUNEL staining is noted below each sample. CD4+ T cells that had been irradiated with 100 Gy {gamma}-irradiation 24 h previously served as positive controls for the assay. Apoptosis values shown represent the mean of three separate experiments.

 
It is possible that the lack of proliferation noted in cultures with 3D6 results from increased cell death. Others have reported that 3D8 and 3D6 mAbs mediate Ag-specific apoptosis of T cell blasts or T cell clones (8). Since this would be inconsistent with the proposed role for CTLA-4 in anergy, we tested the effect of CTLA-4 engagement on bcl-XL induction early after T cell activation (Fig. 2Go, A and B). Resting T cells had low levels of bcl-XL mRNA, which is substantially enhanced following stimulation with anti-CD3/28 alone or anti-CD3/28/MHC I. A similar amount of bcl-XL was present in cultures stimulated with anti-CD3/28 and either inhibitory (3D6) or noninhibitory (3D8) CTLA-4 mAb. No induction of bcl-XL was evident even after 48 h, when samples were stimulated under conditions that did not include anti-CD28 mAbs (Fig. 2GoB). Further, the addition of beads containing anti-CD3/28 and inhibitory anti-CTLA-4 mAb did not inhibit bcl-XL induction or proliferative responses in CD3/28-stimulated CD4+ T cells (data not shown). These data suggest that cross-linking CTLA-4 has no direct effect on bcl-XL induction in the absence of CD28 and support the dominant role that CD28 exhibits within our system. Finally, immunoprecipitation and Western analysis (Fig. 2GoC) of cultures stimulated with anti-CD3/28/glycophorin A, anti-CD3/28/CTLA4 3D8, or anti-CD3/28/CTLA4 3D6 all induced similar amounts of Bcl-XL. No Bcl-XL was induced in lysates from unstimulated cells. Thus, cells stimulated with anti-CD3/28 under conditions that induce IL-2 expression or stimulated with anti-CD3/28/CTLA-4 to block IL-2 expression express similar amounts of bcl-XL at both the mRNA and protein levels. Additionally, the anti-CTLA-4 mAb 3D6 did not induce apoptosis via a bcl-XL-independent pathway inasmuch as in all experimental samples <4% were apoptotic by TUNEL analysis (Fig. 2CGo, bottom). These data suggest that the pathways regulating IL-2 production and bcl-XL expression are differentially influenced by a CTLA-4-induced block.

Previous studies have shown that CTLA-4 mAbs induce a G-S block in cell cycle progression but did not permit discrimination between a G0 and G1 cell cycle arrest (19). To further characterize the mechanism underlying the pronounced decrease in T cell proliferation and IL-2 secretion noted in cultures stimulated with anti-CD3/28 and 3D6, we measured mean cell volume as T cells progressed through the cell cycle (Fig. 3Go). We found that anti-CD3/28-stimulated CD4 T cells had an increased cell volume 4 h after stimulation with a significant increase at 24 h as cells entered S phase (Fig. 3Go). In marked contrast, anti-CD3/28/CTLA-4 3D6-stimulated cells did not increase cell volume for the first 12 h of culture. Abrogation of this marker of T cell activation is consistent with the timing of the block in IL-2 mRNA induction previously observed. In contrast, most cells stimulated with CD3/28/CTLA-4 3D6 mAb remained in G0 as seen in Fig. 4Go. Bivariate plots of the cell cycle data are consistent with the induction of exponential proliferation in the anti-CD3/28 or CD3/28/CTLA-4 3D8-stimulated cultures, with only 10 to 14% of cells remaining in G0 phase of the cell cycle after a 72-h culture. Together, our data indicate that some CTLA-4 mAbs deliver a potent signal that induces a cell cycle arrest in G0 and prevents the induction of IL-2 secretion, while preserving the induction of the cell survival gene bcl-XL.



View larger version (31K):
[in this window]
[in a new window]
  		FIGURE 3. Kinetics of cell sizing after activation with beads coated with anti-CD3/28 or anti-CD3/28/CTLA-4 3D6 mAb. Cell volume was measured using a Coulter Channelyzer and 256 channel histograms displayed. The anti-CD28-CTLA-4 ratio of the beads in this experiment was 1:9. Note that the gaussian shape of the histogram after 24 h of CD3/28 stimulation is consistent with a modest size increase that occurred in all cells. In contrast, anti-CD3/28/3D6 stimulated cells exhibited minimal size increase during the initial 24 h following stimulation. No increase in cell size was noted in cells cultured in medium alone (data not shown).

 


View larger version (45K):
[in this window]
[in a new window]
  		FIGURE 4. CTLA-4 ligation by mAb 3D6 induces a cell cycle arrest at the G0 to G1. transition in CD4+ T cells during the first 4 h of culture. After 72 h of culture in medium alone, or following stimulation with anti-CD3/28 or anti-CD3/28 and the anti-CTLA-4 mAbs 3D6 or 3D8, CD4+ cells were harvested and subjected to simultaneous analysis of cellular RNA and DNA content by staining with pyronin Y and Hoechst 33342 as described in Materials and Methods. The percentage of cells in G0 is indicated for each condition at the bottom of each panel. Data shown are representative of four separate experiments.

 
In this study, we examined whether TCR, CD28, and CTLA-4 interactions have a specialized role in the regulation of cell cycle progression and T cell-proliferative responses of CD4 T cells. The results presented here are the first to demonstrate potent inhibitory effects of CTLA-4 on resting human T cells. CTLA-4-mediated inhibition is uniquely capable of regulating T cell activation and survival in that it can prevent IL-2 induction while not interfering with CD28-mediated bcl-XL induction, suggesting that CTLA-4 inhibits a subset of TCR and CD28-mediated activation signals. Together, our results suggest that the unique role of CTLA-4 signaling is not merely to down-regulate T cell responses late after activation during the time of clonal contraction but also to regulate the threshold of initial T cell activation. In this regard, our data tend to support the notion proposed by Allison and coworkers that a major function of CTLA-4 may be to set the threshold for activation above the level encountered by T cells as a result of the intrinsic affinity of self MHC (27). It is also possible that CTLA-4 has a role in the later down-regulation of ongoing immune responses and this would be consistent with the observed kinetics of CTLA-4 expression that peak 2 to 3 days after activation in vitro. Indeed, these two potential functions of CTLA-4 are not mutually exclusive. Clearly, understanding the CTLA-4 pathway will lead to insights for novel approaches for use in immunoregulation.


   Acknowledgments
 
We thank Dr. Richard Hodes for constructive comments and Gil McCrary, David Ritchey, and Amy Mosquera for excellent technical and administrative assistance. We are grateful for the help of Jason Jussif, Agnes Ciarletta and the Antibody Technology Group at Genetics Institute for preparation and characterization of the anti-CTLA4 Abs. We thank Julio Cotte and the staff at the National Naval Medical Center Blood Bank for their assistance in drawing blood.


   Footnotes
 
1 Supported by the Naval Medical Research and Development Command and by Army Contract DAMD17-93-V-3004. The views expressed in this article are those of the authors and do not reflect the official policy or position of the Department of the Navy, Army, Department of Defense or the U.S. government. Back

2 Address correspondence and reprint requests to Dr. Carl H. June, Immune Cell Biology Program (061), Naval Medical Research Institute, 8901 Wisconsin Avenue, Bethesda, MD 20889-5607. E-mail address: Back

Received for publication September 12, 1997. Accepted for publication October 23, 1997.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results and Discussion
 References
 

  1. Bluestone, J. A.. 1997. Is CTLA-4 a master switch for peripheral T cell tolerance?. J. Immunol. 158:1989.[Abstract]
  2. Linsley, P. S., P. Golstein. 1996. Lymphocyte activation: T-cell regulation by CTLA-4. Curr. Biol. 6:398.[Medline]
  3. van der Merwe, P. A., D. L. Bodian, S. Daenke, P. Linsley, S. J. Davis. 1997. CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. J. Exp. Med. 185:393.[Abstract/Free Full Text]
  4. Lindsten, T., K. P. Lee, E. S. Harris, B. Petryniak, N. Craighead, P. J. Reynolds, D. B. Lombard, G. J. Freeman, L. M. Nadler, G. S. Gray, C. B. Thompson, C. H. June. 1993. Characterization of CTLA-4 structure and expression on human T-cells. J. Immunol. 151:3489.[Abstract]
  5. Finn, P. W., H. He, Y. Wang, Z. Wang, G. Guan, J. Listman, D. L. Perkins. 1997. Synergistic induction of CTLA-4 expression by costimulation with TCR plus CD28 signals mediated by increased transcription and messenger ribonucleic acid stability. J. Immunol. 158:4074.[Abstract]
  6. Linsley, P. S., J. L. Greene, P. Tan, J. Bradshaw, J. A. Ledbetter, C. Anasetti, N. K. Damle. 1992. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J. Exp. Med. 176:1595.[Abstract/Free Full Text]
  7. Walunas, T. L., D. J. Lenschow, C. Y. Bakker, P. S. Linsley, G. J. Freeman, J. M. Green, C. B. Thompson, J. A. Bluestone. 1994. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1:405.[Medline]
  8. Gribben, J. G., G. J. Freeman, V. A. Boussiotis, P. Rennert, C. L. Jellis, E. Greenfield, M. Barber, V. A. Restivo, X. Jr, G. S. Ke, G. S. Gray, L. M. Nadler. 1995. CTLA4 mediates antigen-specific apoptosis of human T cells. Proc. Natl. Acad. Sci. USA 92:811.[Abstract/Free Full Text]
  9. Hansen, J. A., P. J. Martin, R. C. Nowinski. 1980. Monoclonal antibodies identifying a novel T-cell antigen and Ia antigens of human lymphocytes. Immunogenetics 10:247.
  10. June, C. H., J. A. Ledbetter, M. M. Gillespie, T. Lindsten, C. B. Thompson. 1987. T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression. Mol. Cell. Biol. 7:4472.[Abstract/Free Full Text]
  11. Levine, B. L., J. Mosca, J. L. Riley, R. G. Carroll, M. T. Vahey, L. Jagodizinski, K. F. Wagner, D. L. Mayers, D. S. Burke, O. S. Weislow, D. C. St. Louis, C. H. June. 1996. Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation. Science 272:1939.[Abstract]
  12. Crissman, H. A., Z. Darzynkiewicz, J. A. Steinkamp, R. A. Tobey. 1990. Simultaneous fluorescent labeling of DNA,RNA, and protein. Z. Darzynkiewicz, and H. A. Crissman, and J. P. Robinson, eds. Methods in Cell Biology: Flow Cytometry 1st Ed.305. Academic Press, San Diego, CA.
  13. Blair, P. J., L. H. Boise, S. P. Perfetto, B. L. Levine, G. McCrary, K. F. Wagner, D. C. St. Louis, C. B. Thompson, J. N. Siegel, C. H. June. 1997. Impaired induction of the apoptosis-protective protein Bcl-XL in asymptomatic HIV-infected individuals. J. Clin. Immunol. 17:234.[Medline]
  14. Gottschalk, A. R., L. H. Boise, C. B. Thompson, J. Quintans. 1994. Identification of immunosuppressant-induced apoptosis in a murine B-cell line and its prevention by bcl-x but not bcl-2. Proc. Natl. Acad. Sci. USA 91:7350.[Abstract/Free Full Text]
  15. Vahey, M. T., M. T. Wong. 1995. Quantitative liquid hybridization PCR method employing storage phosphor technology. C. W. Dieffenbach, and G. S. Dveksler, eds. PCR Primer: A Laboratory Manual 313. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
  16. Wu, Y., Y. Guo, A. Huang, P. Zheng, Y. Liu. 1997. CTLA-4-B7 interaction is sufficient to costimulate T cell clonal expansion. J. Exp. Med. 185:1327.[Abstract/Free Full Text]
  17. Krummel, M. F., J. P. Allison. 1995. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182:459.[Abstract/Free Full Text]
  18. Chambers, C. A., J. P. Allison. 1997. Co-stimulation in T cell responses. Curr. Opin. Immunol. 9:396.[Medline]
  19. Krummel, M. F., J. P. Allison. 1996. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J. Exp. Med. 183:2533.[Abstract/Free Full Text]
  20. Walunas, T. L., C. Y. Bakker, J. A. Bluestone. 1996. CTLA-4 ligation blocks CD28-dependent T cell activation. J. Exp. Med. 183:2541.[Abstract/Free Full Text]
  21. Green, J. M., P. J. Noel, A. I. Sperling, T. L. Walunas, G. S. Gray, J. A. Bluestone, C. B. Thompson. 1994. Absence of B7-dependent responses in CD28-deficient mice. Immunity 1:501.[Medline]
  22. Damle, N. K., K. Klussman, G. Leytze, S. Myrdal, A. Aruffo, J. A. Ledbetter, P. S. Linsley. 1994. Costimulation of T lymphocytes with integrin ligands intercellular adhesion molecule-1 or vascular cell adhesion molecule-1 induces functional expression of CTLA-4, a second receptor for B7. J. Immunol. 152:2686.[Abstract]
  23. Linsley, P. S.. 1995. Distinct roles for CD28 and cytotoxic T lymphocyte-associated molecule- 4 receptors during T cell activation?. J. Exp. Med. 182:289.[Free Full Text]
  24. Sperling, A. I., J. A. Auger, B. D. Ehst, I. C. Rulifson, C. B. Thompson, J. A. Bluestone. 1996. CD28/B7 interactions deliver a unique signal to naive T cells that regulates cell survival but not early proliferation. J. Immunol. 157:3909.[Abstract]
  25. Boise, L. H., A. J. Minn, M. A. Accavitti, C. H. June, T. Lindsten, C. B. Thompson. 1995. CD28 costimulation can promote T cell survival by inducing the expression of Bcl-Xl. Immunity 3:87.[Medline]
  26. Perez, V. L., L. Van Parijs, A. Biuckians, X. X. Zheng, T. B. Strom, A. K. Abbas. 1997. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 6:411.[Medline]
  27. Chambers, C. A., M. F. Krummel, B. Boitel, A. Hurwitz, T. J. Sullivan S. Fournier, D. Cassell, M. Brunner, J. P. Allison. 1996. The role of CTLA-4 in the regulation and initiation of T-cell responses. Immunol. Rev. 153:27.[Medline]



This article has been cited by other articles:


Home page
 J. Immunol.Home page
H. Hoff, K. Knieke, Z. Cabail, H. Hirseland, G. Vratsanos, G.-R. Burmester, G. Jorch, S. G. Nadler, B. Broker, K. Hebel, et al.
Surface CD152 (CTLA-4) Expression and Signaling Dictates Longevity of CD28null T Cells
J. Immunol., May 1, 2009; 182(9): 5342 - 5351.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. G. Zheng, J. H. Wang, W. Stohl, K. S. Kim, J. D. Gray, and D. A. Horwitz
TGF-beta Requires CTLA-4 Early after T Cell Activation to Induce FoxP3 and Generate Adaptive CD4+CD25+ Regulatory Cells
J. Immunol., March 15, 2006; 176(6): 3321 - 3329.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
D. Homann, W. Dummer, T. Wolfe, E. Rodrigo, A. N. Theofilopoulos, M. B. A. Oldstone, and M. G. von Herrath
Lack of Intrinsic CTLA-4 Expression Has Minimal Effect on Regulation of Antiviral T-Cell Immunity
J. Virol., January 1, 2006; 80(1): 270 - 280.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
R. V. Parry, J. M. Chemnitz, K. A. Frauwirth, A. R. Lanfranco, I. Braunstein, S. V. Kobayashi, P. S. Linsley, C. B. Thompson, and J. L. Riley
CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms
Mol. Cell. Biol., November 1, 2005; 25(21): 9543 - 9553.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
S. Mukherjee, A. Ahmed, and D. Nandi
CTLA4-CD80/CD86 interactions on primary mouse CD4+ T cells integrate signal-strength information to modulate activation with Concanavalin A
J. Leukoc. Biol., July 1, 2005; 78(1): 144 - 157.
[Abstract] [Full Text] [PDF]

Home page
 Am J Trop Med HygHome page
D. S. CARROLL, J. N. MILLS, J. M. MONTGOMERY, D. G. BAUSCH, P. J. BLAIR, J. P. BURANS, V. FELICES, A. GIANELLA, N. IIHOSHI, S. T. NICHOL, et al.
HANTAVIRUS PULMONARY SYNDROME IN CENTRAL BOLIVIA: RELATIONSHIPS BETWEEN RESERVOIR HOSTS, HABITATS, AND VIRAL GENOTYPES
Am J Trop Med Hyg, January 1, 2005; 72(1): 42 - 46.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. L. Riley and C. H. June
The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation
Blood, January 1, 2005; 105(1): 13 - 21.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Inobe and R. H. Schwartz
CTLA-4 Engagement Acts as a Brake on CD4+ T Cell Proliferation and Cytokine Production but Is Not Required for Tuning T Cell Reactivity in Adaptive Tolerance
J. Immunol., December 15, 2004; 173(12): 7239 - 7248.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G. L. Stephens, R. S. McHugh, M. J. Whitters, D. A. Young, D. Luxenberg, B. M. Carreno, M. Collins, and E. M. Shevach
Engagement of Glucocorticoid-Induced TNFR Family-Related Receptor on Effector T Cells by its Ligand Mediates Resistance to Suppression by CD4+CD25+ T Cells
J. Immunol., October 15, 2004; 173(8): 5008 - 5020.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. M. Chemnitz, R. V. Parry, K. E. Nichols, C. H. June, and J. L. Riley
SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation
J. Immunol., July 15, 2004; 173(2): 945 - 954.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
L. A. Yi, S. Hajialiasgar, and E. Chuang
Tyrosine-mediated inhibitory signals contribute to CTLA-4 function in vivo
Int. Immunol., April 1, 2004; 16(4): 539 - 547.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
P. Pandiyan, D. Gartner, O. Soezeri, A. Radbruch, K. Schulze-Osthoff, and M. C. Brunner-Weinzierl
CD152 (CTLA-4) Determines the Unequal Resistance of Th1 and Th2 Cells against Activation-induced Cell Death by a Mechanism Requiring PI3 Kinase Function
J. Exp. Med., March 15, 2004; 199(6): 831 - 842.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
E. Siu, B. M. Carreno, and J. Madrenas
TCR subunit specificity of CTLA-4-mediated signaling
J. Leukoc. Biol., December 1, 2003; 74(6): 1102 - 1107.
[Abstract] [Full Text]

Home page
 BloodHome page
B. Vanhove, G. Laflamme, F. Coulon, M. Mougin, P. Vusio, F. Haspot, J. Tiollier, and J.-P. Soulillou
Selective blockade of CD28 and not CTLA-4 with a single-chain Fv-{alpha}1-antitrypsin fusion antibody
Blood, July 15, 2003; 102(2): 564 - 570.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
R. V. Parry, C. A. Rumbley, L. H. Vandenberghe, C. H. June, and J. L. Riley
CD28 and Inducible Costimulatory Protein Src Homology 2 Binding Domains Show Distinct Regulation of Phosphatidylinositol 3-Kinase, Bcl-xL, and IL-2 Expression in Primary Human CD4 T Lymphocytes
J. Immunol., July 1, 2003; 171(1): 166 - 174.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. Steel and T. B. Nutman
CTLA-4 in Filarial Infections: Implications for a Role in Diminished T Cell Reactivity
J. Immunol., February 15, 2003; 170(4): 1930 - 1938.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
F. Bennett, D. Luxenberg, V. Ling, I-M. Wang, K. Marquette, D. Lowe, N. Khan, G. Veldman, K. A. Jacobs, V. E. Valge-Archer, et al.
Program Death-1 Engagement Upon TCR Activation Has Distinct Effects on Costimulation and Cytokine-Driven Proliferation: Attenuation of ICOS, IL-4, and IL-21, But Not CD28, IL-7, and IL-15 Responses
J. Immunol., January 15, 2003; 170(2): 711 - 718.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
S. Mukherjee, P. K. Maiti, and D. Nandi
Role of CD80, CD86, and CTLA4 on mouse CD4+ T lymphocytes in enhancing cell-cycle progression and survival after activation with PMA and ionomycin
J. Leukoc. Biol., November 1, 2002; 72(5): 921 - 931.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. L. Riley, M. Mao, S. Kobayashi, M. Biery, J. Burchard, G. Cavet, B. P. Gregson, C. H. June, and P. S. Linsley
Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors
PNAS, September 3, 2002; 99(18): 11790 - 11795.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
P. J. Darlington, M. L. Baroja, T. A. Chau, E. Siu, V. Ling, B. M. Carreno, and J. Madrenas
Surface Cytotoxic T Lymphocyte-associated Antigen 4 Partitions Within Lipid Rafts and Relocates to the Immunological Synapse under Conditions of Inhibition of T Cell Activation
J. Exp. Med., May 20, 2002; 195(10): 1337 - 1347.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. Guntermann and D. R. Alexander
CTLA-4 Suppresses Proximal TCR Signaling in Resting Human CD4+ T Cells by Inhibiting ZAP-70 Tyr319 Phosphorylation: A Potential Role for Tyrosine Phosphatases
J. Immunol., May 1, 2002; 168(9): 4420 - 4429.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
F. Haspot, F. Villemain, G. Laflamme, F. Coulon, D. Olive, J. Tiollier, J.-P. Soulillou, and B. Vanhove
Differential effect of CD28 versus B7 blockade on direct pathway of allorecognition and self-restricted responses
Blood, March 15, 2002; 99(6): 2228 - 2234.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M.-N. Avice, M. Rubio, M. Sergerie, G. Delespesse, and M. Sarfati
Role of CD47 in the Induction of Human Naive T Cell Anergy
J. Immunol., September 1, 2001; 167(5): 2459 - 2468.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. L. Riley, P. J. Blair, J. T. Musser, R. Abe, K. Tezuka, T. Tsuji, and C. H. June
ICOS Costimulation Requires IL-2 and Can Be Prevented by CTLA-4 Engagement
J. Immunol., April 15, 2001; 166(8): 4943 - 4948.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. da Rocha Dias and C. E. Rudd
CTLA-4 blockade of antigen-induced cell death
Blood, February 15, 2001; 97(4): 1134 - 1137.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. P. M. Broeren, G. S. Gray, B. M. Carreno, and C. H. June
Costimulation Light: Activation of CD4+ T Cells with CD80 or CD86 Rather Than Anti-CD28 Leads to a Th2 Cytokine Profile
J. Immunol., December 15, 2000; 165(12): 6908 - 6914.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Y. Yi, M. McNerney, and S. K. Datta
Regulatory Defects in Cbl and Mitogen-Activated Protein Kinase (Extracellular Signal-Related Kinase) Pathways Cause Persistent Hyperexpression of CD40 Ligand in Human Lupus T Cells
J. Immunol., December 1, 2000; 165(11): 6627 - 6634.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T. Iida, H. Ohno, C. Nakaseko, M. Sakuma, M. Takeda-Ezaki, H. Arase, E. Kominami, T. Fujisawa, and T. Saito
Regulation of Cell Surface Expression of CTLA-4 by Secretion of CTLA-4-Containing Lysosomes Upon Activation of CD4+ T Cells
J. Immunol., November 1, 2000; 165(9): 5062 - 5068.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
G. J. Freeman, A. J. Long, Y. Iwai, K. Bourque, T. Chernova, H. Nishimura, L. J. Fitz, N. Malenkovich, T. Okazaki, M. C. Byrne, et al.
Engagement of the PD-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
J. Exp. Med., October 2, 2000; 192(7): 1027 - 1034.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
T. McGaha and J. W. Murphy
CTLA-4 Down-Regulates the Protective Anticryptococcal Cell-Mediated Immune Response
Infect. Immun., August 1, 2000; 68(8): 4624 - 4630.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
B. M. Carreno, F. Bennett, T. A. Chau, V. Ling, D. Luxenberg, J. Jussif, M. L. Baroja, and J. Madrenas
CTLA-4 (CD152) Can Inhibit T Cell Activation by Two Different Mechanisms Depending on Its Level of Cell Surface Expression
J. Immunol., August 1, 2000; 165(3): 1352 - 1356.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. D. Griffin, D. K. Hong, P. O. Holman, K.-M. Lee, M. J. Whitters, S. M. O'Herrin, F. Fallarino, M. Collins, D. M. Segal, T. F. Gajewski, et al.
Blockade of T Cell Activation Using a Surface-Linked Single-Chain Antibody to CTLA-4 (CD152)
J. Immunol., May 1, 2000; 164(9): 4433 - 4442.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. L. Baroja, D. Luxenberg, T. Chau, V. Ling, C. A. Strathdee, B. M. Carreno, and J. Madrenas
The Inhibitory Function of CTLA-4 Does Not Require Its Tyrosine Phosphorylation
J. Immunol., January 1, 2000; 164(1): 49 - 55.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
F. P. Heinzel and R. A. Maier Jr.
Interleukin-4-Independent Acceleration of Cutaneous Leishmaniasis in Susceptible BALB/c Mice following Treatment with Anti-CTLA4 Antibody
Infect. Immun., December 1, 1999; 67(12): 6454 - 6460.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
C. Nakaseko, S. Miyatake, T. Iida, S. Hara, R. Abe, H. Ohno, Y. Saito, and T. Saito
Cytotoxic T Lymphocyte Antigen 4 (CTLA-4) Engagement Delivers an Inhibitory Signal through the Membrane-proximal Region in the Absence of the Tyrosine Motif in the Cytoplasmic Tail
J. Exp. Med., September 20, 1999; 190(6): 765 - 774.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
P. J. Perrin, C. H. June, J. H. Maldonado, R. B. Ratts, and M. K. Racke
Blockade of CD28 During In Vitro Activation of Encephalitogenic T Cells or After Disease Onset Ameliorates Experimental Autoimmune Encephalomyelitis
J. Immunol., August 1, 1999; 163(3): 1704 - 1710.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C. A. Chambers, M. S. Kuhns, and J. P. Allison
Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates primary and secondary peptide-specific CD4+ T cell responses
PNAS, July 20, 1999; 96(15): 8603 - 8608.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
J. L. Riley, K. Schlienger, P. J. Blair, B. Carreno, N. Craighead, D. Kim, R. G. Carroll, and C. H. June
Modulation of Susceptibility to HIV-1 Infection by the Cytotoxic T Lymphocyte Antigen 4 Costimulatory Molecule
J. Exp. Med., June 6, 1999; 191(11): 1987 - 1998.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
R. Khattri, J. A. Auger, M. D. Griffin, A. H. Sharpe, and J. A. Bluestone
Lymphoproliferative Disorder in CTLA-4 Knockout Mice Is Characterized by CD28-Regulated Activation of Th2 Responses
J. Immunol., May 15, 1999; 162(10): 5784 - 5791.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. C. Brunner, C. A. Chambers, F. K.-M. Chan, J. Hanke, A. Winoto, and J. P. Allison
CTLA-4-Mediated Inhibition of Early Events of T Cell Proliferation
J. Immunol., May 15, 1999; 162(10): 5813 - 5820.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
D. Saverino, C. Tenca, D. Zarcone, A. Merlo, A. M. Megiovanni, M. T. Valle, F. Manca, C. E. Grossi, and E. Ciccone
CTLA-4 (CD152) Inhibits the Specific Lysis Mediated by Human Cytolytic T Lymphocytes in a Clonally Distributed Fashion
J. Immunol., January 15, 1999; 162(2): 651 - 658.
[Abstract] [Full Text] [PDF]

Home page
 Cold Spring Harb Symp Quant BiolHome page
C.A. CHAMBERS and J.P. ALLISON
CTLA-4 -- The Costimulatory Molecule That Doesn't: Regulation of T-cell Responses by Inhibition
Cold Spring Harb Symp Quant Biol, January 1, 1999; 64(0): 303 - 312.
[Abstract] [PDF]

Home page
 J. Immunol.Home page
M.-L. Alegre, H. Shiels, C. B. Thompson, and T. F. Gajewski
Expression and Function of CTLA-4 in Th1 and Th2 Cells
J. Immunol., October 1, 1998; 161(7): 3347 - 3356.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. Schlienger, K. Uyemura, D. Jullien, P. A. Sieling, T. H. Rea, P. S. Linsley3, and R. L. Modlin
B7-1, But Not CD28, Is Crucial for the Maintenance of the CD4+ T Cell Responses in Human Leprosy
J. Immunol., September 1, 1998; 161(5): 2407 - 2413.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
P. Scheipers and H. Reiser
Fas-independent death of activated CD4+ T lymphocytes induced by CTLA-4 crosslinking
PNAS, August 18, 1998; 95(17): 10083 - 10088.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. H. Horspool, P. J. Perrin, J. B. Woodcock, J. H. Cox, C. L. King, C. H. June, D. M. Harlan, D. C. St. Louis, and K. P. Lee
Nucleic Acid Vaccine-Induced Immune Responses Require CD28 Costimulation and Are Regulated by CTLA4
J. Immunol., March 15, 1998; 160(6): 2706 - 2714.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Blair, P. J.
Right arrow Articles by June, C. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blair, P. J.
Right arrow Articles by June, C. H.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS